News

Keep up with the latest news from the NCI Center for Biomedical Informatics and Information Technology (CBIIT) and the data science communities.

A new, scalable, machine learning model is helping scientists model thousands of transcription factors and genes in the human genome, providing new information on these genes and how they work/change over time.

With the help of machine learning, NCI-funded researchers were able to boost the prognostic power of a common blood test for liver cancer.

Interpreting whole slide images can be a labor intensive and difficult task. A recent article describes a new approach that helps classify cancer and predict how it will progress.

Are you developing machine learning and looking for ways to make your model generalizable to a diverse population? A recent study describes an algorithm that centers on transforming your data rather than tweaking your model.

NCI-funded researchers used machine learning to characterize a cancer biomarker based on exosomes. Their biomarker worked well using non-invasive sources, such as blood and urine, allowing the researchers to catch cancer early, even in tumors of undetermined origins.

See how NCI researchers are using artificial intelligence to develop tools that may someday help oncologists make more informed decisions when caring for people with prostate cancer.

NCI-funded researchers are using machine learning to help identify an early-warning screening approach for colorectal cancer.

Are you researching immunotherapies and having trouble predicting which epitope will deliver the biggest punch? Try this new model for predicting immunogenicity, which is reportedly outperforming current models.

In the “Mitelman Gene Fusions in TCGA” notebook, ISB Cancer Gateway in the Cloud (an NCI Cloud Resource) identified the most common gene fusions in prostate adenocarcinoma, demonstrating machine learning in Google BigQuery.

A new machine learning model blends image data with clinical and pathological information to tailor care for patients with breast cancer.